Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:283-288
Published online before print December 26, 2002, doi: 10.1161/01.ATV.0000054195.35121.5E
Published online before print December 26, 2002, doi: 10.1161/01.ATV.0000054195.35121.5E
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Antidiabetic PPAR
-Activator Rosiglitazone Reduces MMP-9 Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease
From the Department of Internal Medicine II–Cardiology (N.M., J.F., L.S., J.I., V.H., W.K.), University of Ulm, Hospital of Heidenheim (G.W., A.S.), Teaching Hospital of the University of Ulm, and Department of Clinical Chemistry (H.S.), University of Freiburg, Germany.
Correspondence to Nikolaus Marx, MD, Department of Internal Medicine II–Cardiology, University of Ulm, Robert-Koch-Str 8, D-89081 Ulm, Germany. E-mail nikolaus.marx{at}medizin.uni-ulm.de
Background— Matrix metalloproteinases (MMPs) are critically involved in the development of unstable plaques. Although arteriosclerotic lesions in patients with diabetes mellitus are more unstable than those of nondiabetic subjects, nothing is known about serum levels of MMPs in these patients or about mechanisms to modulate MMP levels. We investigated MMP levels in diabetic and nondiabetic coronary artery disease (CAD) patients and performed a clinical trial to assess the effect of the PPAR
-activating, antidiabetic thiazolidinedione rosiglitazone on MMP levels in diabetic CAD patients.
Methods and Results— In CAD patients, MMP-2, -8, and -9 serum levels were significantly higher in type 2 diabetic subjects compared with age-, sex-, and body mass index–matched nondiabetics. Thirty-nine diabetic patients with CAD were randomized to receive rosiglitazone 4 mg (twice daily) or placebo for 12 weeks. Rosiglitazone treatment, but not placebo, significantly reduced MMP-9 levels already after 2 weeks by -19.6% (-38.3% to 8.6%, P<0.05), and levels remained suppressed until the end of the study. In addition, rosiglitazone significantly decreased serum amyloid A (SAA) and tumor necrosis factor-
levels.
Conclusion— MMP-9 levels are increased in type 2 diabetic patients with CAD, and treatment of these patients with the antidiabetic PPAR-activator rosiglitazone significantly reduces MMP-9, tumor necrosis factor-, and SAA serum levels. These data support anti-inflammatory and potential antiatherogenic effects of thiazolidinediones.
Key Words: diabetes • coronary artery disease • PPAR&ggr • matrix metalloproteinases • thiazolidinediones
This article has been cited by other articles:
 |
|
 |
|
  M. R. Dasu, S. Park, S. Devaraj, and I. Jialal Pioglitazone Inhibits Toll-Like Receptor Expression and Activity in Human Monocytes and db/db Mice Endocrinology, August 1, 2009; 150(8): 3457 - 3464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jones, R. Deb, E. Torsney, F. Howe, M. Dunkley, Y. Gnaneswaran, D. Gaze, H. Nasr, I. M. Loftus, M. M. Thompson, et al. Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms Circulation, June 23, 2009; 119(24): 3125 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Hanusch-Enserer, G. Zorn, J. Wojta, C. W. Kopp, R. Prager, W. Koenig, M. Schillinger, M. Roden, and K. Huber Non-conventional markers of atherosclerosis before and after gastric banding surgery Eur. Heart J., June 2, 2009; 30(12): 1516 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Marx PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 345 - 346. [PDF]
|
|
|
|
 |
|
 D. F. Lehmann and B. B. Lohray A Lesson in Moderation: Applying Pharmacodynamics to Clarify the Relationship Between Thiazolidinediones and Adverse Vascular Outcomes in Type 2 Diabetes J. Clin. Pharmacol., August 1, 2008; 48(8): 999 - 1002. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ceolotto, A. Gallo, I. Papparella, L. Franco, E. Murphy, E. Iori, E. Pagnin, G. P. Fadini, M. Albiero, A. Semplicini, et al. Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2627 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Fang, Yeun Tarl Fresner Ng Jao, Yi-Chen, C.-L. Yu, C.-L. Chen, and S.-P. Wang Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience Angiology, November 1, 2007; 58(5): 523 - 534. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Schindler Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 7 - 26. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Fischoeder, H. Meyborg, D. Stibenz, E. Fleck, K. Graf, and P. Stawowy Insulin augments matrix metalloproteinase-9 expression in monocytes Cardiovasc Res, March 1, 2007; 73(4): 841 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hanefeld, N. Marx, A. Pfutzner, W. Baurecht, G. Lubben, E. Karagiannis, U. Stier, and T. Forst Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study J. Am. Coll. Cardiol., January 23, 2007; 49(3): 290 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Utzschneider and S. E. Kahn The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4753 - 4761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Gilde, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Third Annual World Congress on the Insulin Resistance Syndrome: Atherothrombotic disease Diabetes Care, August 1, 2006; 29(8): 1973 - 1980. [Full Text] [PDF]
|
|
|
|
|
|
F. Meisner, D. Walcher, F. Gizard, X. Kapfer, R. Huber, A. Noak, L. Sunder-Plassmann, H. Bach, C. Haug, M. Bachem, et al. Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients: Data From a Randomized Placebo-Controlled Trial Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 845 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sawai, J. Liu, H. A. Reber, O. J. Hines, and G. Eibl Activation of Peroxisome Proliferator-Activated Receptor-{gamma} Decreases Pancreatic Cancer Cell Invasion through Modulation of the Plasminogen Activator System Mol. Cancer Res., March 1, 2006; 4(3): 159 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Blaschke, Y. Takata, E. Caglayan, R. E. Law, and W. A. Hsueh Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 28 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Consoli and E Devangelio Thiazolidinediones and inflammation Lupus, September 1, 2005; 14(9): 794 - 797. [Abstract] [PDF]
|
|
|
|
|
|
J. Hetzel, B. Balletshofer, K. Rittig, D. Walcher, W. Kratzer, V. Hombach, H.-U. Haring, W. Koenig, and N. Marx Rapid Effects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1804 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pfutzner, N. Marx, G. Lubben, M. Langenfeld, D. Walcher, T. Konrad, and T. Forst Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic Control: Results From the Pioneer Study J. Am. Coll. Cardiol., June 21, 2005; 45(12): 1925 - 1931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.R. Langenfeld, T. Forst, C. Hohberg, P. Kann, G. Lubben, T. Konrad, S.D. Fullert, C. Sachara, and A. Pfutzner Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study Circulation, May 17, 2005; 111(19): 2525 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Cariou, J.-C. Fruchart, and B. Staels Review: Vascular protective effects of peroxisome proliferator-activated receptor agonists The British Journal of Diabetes & Vascular Disease, May 1, 2005; 5(3): 126 - 132. [Abstract] [PDF]
|
|
|
|
 |
|
 S. S. Signorelli, G. Malaponte, M. Libra, L. D. Pino, G. Celotta, V. Bevelacqua, M. Petrina, G. S Nicotra, M. Indelicato, P. M Navolanic, et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease Vascular Medicine, February 1, 2005; 10(1): 1 - 6. [Abstract] [PDF]
|
|
|
|
 |
|
 A. C. Newby Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture Physiol Rev, January 1, 2005; 85(1): 1 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Moreno and V. Fuster New aspects in the pathogenesis of diabetic atherothrombosis J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2293 - 2300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Moreno and V. Fuster The year in atherothrombosis J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2099 - 2110. [Full Text] [PDF]
|
|
|
|
|
|
D. Choi, S.-K. Kim, S.-H. Choi, Y.-G. Ko, C.-W. Ahn, Y. Jang, S.-K. Lim, H.-C. Lee, and B.-S. Cha Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes Diabetes Care, November 1, 2004; 27(11): 2654 - 2660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Walcher and N. Marx Insulin resistance and cardiovascular disease: the role of PPAR{gamma} activators beyond their anti-diabetic action Diabetes and Vascular Disease Research, October 1, 2004; 1(2): 76 - 81. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Yki-Jarvinen Thiazolidinediones N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118. [Full Text] [PDF]
|
|
|
|
|
|
M. Bajaj, S. Suraamornkul, S. Kashyap, K. Cusi, L. Mandarino, and R. A. DeFronzo Sustained Reduction in Plasma Free Fatty Acid Concentration Improves Insulin Action without Altering Plasma Adipocytokine Levels in Subjects with Strong Family History of Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4649 - 4655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Marx, H. Duez, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors and Atherogenesis: Regulators of Gene Expression in Vascular Cells Circ. Res., May 14, 2004; 94(9): 1168 - 1178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. I. Anderson, F. Wang, and D. G. Gardner Role of the Epidermal Growth Factor Receptor in Signaling Strain-dependent Activation of the Brain Natriuretic Peptide Gene J. Biol. Chem., March 5, 2004; 279(10): 9287 - 9297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Plutzky Peroxisome proliferator-activated receptors as therapeutic targets in inflammation J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1764 - 1766. [Full Text] [PDF]
|
|
|
|
|
|
M. B. Davidson Is Treatment of Insulin Resistance Beneficial Independent of Glycemia? Diabetes Care, November 1, 2003; 26(11): 3184 - 3186. [Full Text] [PDF]
|
|
|
|
|
|
P. E. Szmitko, C.-H. Wang, R. D. Weisel, G. A. Jeffries, T. J. Anderson, and S. Verma Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II Circulation, October 28, 2003; 108(17): 2041 - 2048. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iglarz, R. M. Touyz, E. C. Viel, P. Paradis, F. Amiri, Q. N. Diep, and E. L. Schiffrin Peroxisome Proliferator-Activated Receptor-{alpha} and Receptor-{gamma} Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension Hypertension, October 1, 2003; 42(4): 737 - 743. [Abstract] [Full Text] [PDF]
|
|